GRIFOLS ITALY operating for over 15 years in the distribution of plasma-derived products in our country, having already achieved a leading position in the Italian market.
Ethics and quality of service are the main theme of our business in Italy and in the world, since 1940 in the service of health workers and patients users of our drugs.
Our mission is to bring to Italy all Proteins Plasma derivatives produced in large and modern plants of Parets (Spain) and Los Angeles (USA) and in new plants that will soon be added, with continual improvements in yield, purity and safety and introducing those innovative, currently under research and development.
The Group Grifols collects high quality human plasma through its FDA Approved US centers plasmapheresis .
We provide the Hospital Pharmacies systems for the distribution and monitoring of drugs (Kardex), modular cleanrooms (Misterium®), equipment for the preparation of sterile infusion solutions and products for oncology (Gri-fill® 3.0) and equipment single-dose packaging of drugs destined, in hospital administration, at the bedside (Blispack).
We provide blood and plasma centers bags and equipment for transfusion, the MB-VIP service (methylene Blue Virus Inactivated Plasma) and Advanced technologies for inactivation of pathogens (viruses and bacteria) of platelet concentrates as exclusive distributors for Italy Cerus Intercept technology Inc. This technology provides the advantage to the Italian transfusion centers can also be used for virusinattivazione “in house” Plasma distributed transfusion purposes. In addition we provide medicine Transfusion Italian simple systems and efficient traceability of the transfusion of blood and plasma (Gricode®) with the benefit cost / benefit truly competitive
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the…
In recent years, since the adoption of a law assuring its citizens’ right to access palliative care, Italy has given increased attention to pain management. According to Aldo Sterpone, Italy…
Aldo Sterpone, Grünenthal Italia’s General Manager, outlines the company’s focus on pain and its efforts to bring innovation to the area through R&D and acquisitions. He also explains the importance…
We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company’s approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology,…
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time…
Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges…
Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of…
Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…